Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INV 103

Drug Profile

INV 103

Alternative Names: ala-chaperonin-10; Ala-Cpn10; Chaperonin 10; Cpn 10; Heat shock protein 10 - Invion; HSP-10 - Invion; INV103; Recombinant Cpn 10; XToll

Latest Information Update: 09 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CBio
  • Developer Invion
  • Class Anti-inflammatories; Antirheumatics; Chaperonins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Autoimmune disorders

Highest Development Phases

  • No development reported Multiple sclerosis; Plaque psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus; Ulcerative colitis

Most Recent Events

  • 09 Aug 2019 No development reported - Phase-I/II for Systemic lupus erythematosus in USA (IV)
  • 09 Aug 2019 No development reported - Phase-II for Ulcerative colitis in Australia (IV)
  • 14 Nov 2014 HSP 10 is available for licensing as of 14 Nov 2014. http://inviongroup.com
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top